Belantamab study in participants with Multiple Myeloma (DREAMM-20)

• Research type

  Research Study

• Full title

  Publication of this data is currently deferred.

• IRAS ID

  1006615

• Contact name

• Contact email

  GSKClinicalSupportHD@gsk.com

• Sponsor organisation

  Publication of this data is currently deferred.

• Eudract number

  2022-501941-63

• Clinicaltrials.gov Identifier

  NCT05714839

• Research summary

  Publication of this data is currently deferred.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  23/SC/0039

• Date of REC Opinion

  19 May 2023

• REC opinion

  Further Information Favourable Opinion